SG11202003612VA - Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same - Google Patents

Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Info

Publication number
SG11202003612VA
SG11202003612VA SG11202003612VA SG11202003612VA SG11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA
Authority
SG
Singapore
Prior art keywords
cocrystals
methods
pharmaceutical compositions
treatment involving
involving same
Prior art date
Application number
SG11202003612VA
Other languages
English (en)
Inventor
Benjamin Lane
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of SG11202003612VA publication Critical patent/SG11202003612VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202003612VA 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same SG11202003612VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
SG11202003612VA true SG11202003612VA (en) 2020-05-28

Family

ID=64572453

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003612VA SG11202003612VA (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Country Status (17)

Country Link
US (3) US11345677B2 (es)
EP (1) EP3704101A1 (es)
JP (3) JP7335877B2 (es)
KR (1) KR20200095480A (es)
CN (2) CN111527076B (es)
AU (2) AU2018360827B2 (es)
BR (1) BR112020008598A2 (es)
CA (1) CA3081535A1 (es)
EA (1) EA202091112A1 (es)
IL (2) IL305426B2 (es)
MA (1) MA50526A (es)
MX (2) MX2020004513A (es)
PH (1) PH12020550462A1 (es)
SG (1) SG11202003612VA (es)
TW (2) TWI839131B (es)
UA (1) UA127380C2 (es)
WO (1) WO2019090059A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
WO2022036033A2 (en) 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Solid state forms of an organic compound
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CA3081535A1 (en) 2019-05-09
AU2024203186A1 (en) 2024-05-30
EP3704101A1 (en) 2020-09-09
IL305426B2 (en) 2024-10-01
IL305426B1 (en) 2024-06-01
US11851417B2 (en) 2023-12-26
US20240343705A1 (en) 2024-10-17
AU2018360827B2 (en) 2024-02-22
US20210198234A1 (en) 2021-07-01
IL305426A (en) 2023-10-01
CN111527076A (zh) 2020-08-11
MX2022014792A (es) 2023-01-16
IL274123A (en) 2020-06-30
JP2023093666A (ja) 2023-07-04
JP7335877B2 (ja) 2023-08-30
CN111527076B (zh) 2024-03-12
TWI839131B (zh) 2024-04-11
US11345677B2 (en) 2022-05-31
AU2018360827A1 (en) 2020-05-14
BR112020008598A2 (pt) 2021-01-26
TW201930285A (zh) 2019-08-01
JP2024113028A (ja) 2024-08-21
IL274123B2 (en) 2024-01-01
IL274123B1 (en) 2023-09-01
TW202337885A (zh) 2023-10-01
PH12020550462A1 (en) 2021-03-22
JP7499377B2 (ja) 2024-06-13
CN118359585A (zh) 2024-07-19
MA50526A (fr) 2020-09-09
TWI796377B (zh) 2023-03-21
EA202091112A1 (ru) 2020-07-23
MX2020004513A (es) 2020-09-17
US20220363661A1 (en) 2022-11-17
UA127380C2 (uk) 2023-08-02
JP2021501766A (ja) 2021-01-21
KR20200095480A (ko) 2020-08-10
WO2019090059A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
HK1254525A1 (zh) 治療組合物、組合和使用方法
EP3371306B8 (en) Materials and methods for treatment of hemoglobinopathies
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3341392A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
HK1259372A1 (zh) 治療化合物、其組合物及使用方法
IL269901B (en) Pharmaceutical compounds and methods of treating cardiovascular diseases
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
PL3373910T3 (pl) Preparat echinomycyny, sposób wytwarzania i sposób stosowania
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL274123B1 (en) Co-crystals, their pharmaceutical preparations and treatment methods involving them
HK1217303A1 (zh) 種治療白血病的藥物組合物及其製備方法
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
IL273850A (en) Preparations and methods for the treatment of leprosy
EP3468540A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
HK1258999A1 (zh) 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
EP3258908A4 (en) Compositions and methods for treatment of skin infections
HK1245094A1 (zh) 一種治療抑鬱症的藥物組合物及其製備方法
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
GB201718483D0 (en) Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof
EP3294417A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOMES
PL3270912T4 (pl) Kompozycje farmaceutyczne zawierające kompleksy taksan-cyklodekstryna, sposób wytwarzania i sposoby zastosowania
IL271727A (en) Method of treatment and their dosage forms